Form 4: Sagimet Biosciences Director Jennifer Jarrett Granted Stock Options Valued at $5.33 Per Share

Sagimet Biosciences Inc. Director Jennifer Jarrett has been granted stock options to acquire 27,268 shares of common stock at an exercise price of $5.33 per share, vesting over 12 months.

Summary

• Jennifer Jarrett, a Director of Sagimet Biosciences Inc. (SGMT), was granted stock options.
• The transaction date for this grant was June 9, 2025.
• The options allow for the purchase of 27,268 shares of Series A Common Stock.
• The exercise price for these options is $5.33 per share.
• The options will vest in twelve equal monthly installments starting from June 9, 2025, contingent upon Ms. Jarrett's continued service.
• The expiration date for these stock options is June 8, 2035.
• Following this transaction, Ms. Jarrett directly beneficially owns 27,268 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it represents a routine compensation event that aligns director interests with shareholders, without indicating any negative operational or financial news.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, as the options gain value if the stock price increases.
• The vesting schedule over 12 months encourages continued service and commitment from the director.

Negatives

• The exercise of these options in the future could lead to a minor dilution of existing shareholders' equity, although this is a standard component of executive and director compensation.

Risks

• The value of the stock options is dependent on the future market price of Sagimet Biosciences Inc. common stock; if the stock price does not exceed the exercise price, the options may expire worthless.
• The vesting of options is subject to the reporting person's continued service, meaning unvested options would be forfeited if service ceases.

Future Outlook

The stock options granted to Director Jennifer Jarrett are subject to a 12-month vesting schedule, indicating an expectation of her continued service to Sagimet Biosciences Inc. through at least June 2026.

Management Comments

• The filing indicates a standard grant of stock options to a director, reflecting a common form of compensation and alignment strategy.

Industry Context

The grant of stock options to directors is a common practice across the biotechnology and pharmaceutical industries, serving as a key component of compensation packages designed to attract and retain talent while aligning their interests with long-term shareholder value.

Comparison to Industry Standards

• The grant of stock options to a director is a standard compensation practice in the biotechnology sector, comparable to equity incentive plans seen at companies like Gilead Sciences, Amgen, or Biogen, which frequently use stock options or restricted stock units to compensate their non-employee directors.
• The vesting schedule over 12 months is a relatively short-term vesting period for director options, though monthly installments are common.

Corporate Governance

Related Party Transactions

• The grant of stock options to Jennifer Jarrett, a director of Sagimet Biosciences Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant of options aligns the director's interests with shareholder value creation, but also introduces potential future dilution upon exercise.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The granted stock options will vest in 12 equal monthly installments following June 9, 2025, subject to the director's continued service.

Key Dates

Keywords

Sagimet Biosciences, SGMT, Stock Option, Director Compensation, Insider Transaction, Form 4, Equity Grant, Vesting